Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657134 | 1.00 | GAA (0.31) | GAAPABPC1CTDSP1POLBMAPK1 | |
| SCHEMBL7330626 | 0.97 | — | — | |
| SCHEMBL6395191 | 0.97 | — | — | |
| SCHEMBL18659636 | 0.87 | — | — | |
| SCHEMBL2657412 | 0.84 | POLB (0.31) | GAAPOLBMAPK1NPSR1 | |
| SCHEMBL18655451 | 0.82 | — | — | |
| SCHEMBL18659634 | 0.82 | — | — | |
| SCHEMBL18802254 | 0.79 | HTR1A (0.42) | GAAPOLBMAPK1NPSR1 | |
| SCHEMBL16808417 | 0.79 | HTR1A (0.42) | GAAPOLBMAPK1NPSR1 | |
| SCHEMBL16808637 | 0.79 | HTR1A (0.42) | GAAPOLBMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853409-B2 | Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120277242-A1 | Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| CN-1063753-C | Method for preparing platinum compound | SUNKYONG IND LTD (KR) | 2001-03-28 | — | — | CN | disclosed |
| CN-1204650-A | Method for preparing platinum compound | SUNKYONG IND LTD (KR) | 1999-01-13 | — | — | CN | disclosed |
| CN-1038590-C | Process for preparing platinum complexes | SUNKYONG IND LTD (KR) | 1998-06-03 | — | — | CN | disclosed |
| US-5395947-A | Antitumor agents | SUNKYONG INDUSTRIES, LTD. (KR) | 1995-03-07 | — | — | US | disclosed |
| CN-1065274-A | Platinum complex and preparation method thereof | SUNKYONG IND LTD (KR) | 1992-10-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277242-A1 | Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | GAA 364/4885PABPC1 3744/4885CTDSP1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.